Early treatment with atorvastatin exerts parenchymal and vascular protective effects in experimental cerebral ischaemia

British Journal of Pharmacology

Volumn 172, Issue 21, 2015, Pages 5188-5198

  Potey, C ^a   Ouk, T ^a   Petrault, O ^a   Petrault, M ^a   Berezowski, V ^a   Salleron, J ^a   Bordet, R ^a   Gautier, S ^a  

^a UNIV LILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; COLLAGEN TYPE 4; DEXTRAN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NEUROPROTECTIVE AGENT;

ACUTE DRUG ADMINISTRATION; ADHESIVE REMOVAL TEST; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD VESSEL PARAMETERS; BLOOD VESSEL REACTIVITY; BRAIN ISCHEMIA; BRAIN PROTECTION; CAPILLARY DENSITY; CELL ACTIVATION; CELL INFILTRATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MEGADOSE; EARLY INTERVENTION; ENDOTHELIAL DYSFUNCTION; FOLLOW UP; GRIP STRENGTH; INFARCT VOLUME; LEUKOCYTE ADHERENCE; MALE; MICROGLIA; MICROVASCULAR PATENCY; MIDDLE CEREBRAL ARTERY; MIDDLE CEREBRAL ARTERY OCCLUSION; MOUSE; NERVOUS SYSTEM PARAMETERS; NEUROLOGIC DISEASE ASSESSMENT; NEUROPROTECTION; NONHUMAN; PARENCHYMAL PROTECTION; PRIORITY JOURNAL; VASCULAR PROTECTION; ANIMAL; BRAIN; C57BL MOUSE; DRUG EFFECTS; PATHOPHYSIOLOGY; STROKE; VASCULAR ENDOTHELIUM;

ANIMALS; ATORVASTATIN CALCIUM; BRAIN; ENDOTHELIUM, VASCULAR; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MICE; MICE, INBRED C57BL; NEUROPROTECTIVE AGENTS; STROKE;

EID: 84945944740     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13285     Document Type: Article

References (40)

1. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al., (2013). The Concise Guide to PHARMACOLOGY 2013/14: enzymes. Br J Pharmacol 170: 1797-1867.
2. Amarenco P, Bogousslavsky J, Callahan A, Goldstein LB, Hennerici M, Rudolph AE, et al., (2006). High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 355: 549-59.
3. Bederson JB, Pitts LH, Tsuji M, Nishimura MC, Davis RL, Bartkowski H, (1986). Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. Stroke 17: 472-6.
4. Berger C, Xia F, Maurer M, Schwab S, (2008). Neuroprotection by pravastatin in acute ischemic stroke in rats. Brain Res Rev 58: 48-56.
5. Bouet V, Boulouard M, Toutain J, Divoux D, Bernaudin M, Schumann-Bard P, et al., (2009). The adhesive removal test: a sensitive method to assess sensorimotor deficits in mice. Nat Protoc 4: 1560-1564.
6. Céspedes-Rubio A, Jurado F, Cardona-Gõmez G, (2010). p120 catenin/αN-catenin are molecular targets in the neuroprotection and neuronal plasticity mediated by atorvastatin after focal cerebral ischemia. J Neurosci Res 88: 3621-34.
7. Chen J, Zhang ZG, Li Y, Wang Y, Wang L, Jiang H, et al., (2003). Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke. Ann Neurol 53: 743-51.
8. Cui L, Zhang X, Yang R, Wang L, Liu L, Li M, et al., (2010). Neuroprotection of early and short-time applying atorvastatin in the acute phase of cerebral ischemia: down-regulated 12/15-LOX, p38MAPK and cPLA2 expression, ameliorated BBB permeability. Brain Res 1325: 164-73.
9. Endres M, Laufs U, Huang Z, Nakamura T, Huang P, Moskowitz MA, et al., (1998). Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci 95: 8880-5.
10. Flint AC, Kamel H, Navi BB, Rao VA, Faigeles BS, Conell C, et al., (2012a). Inpatient statin use predicts improved ischemic stroke discharge disposition. Neurology 78: 1678-1683.
11. Flint AC, Kamel H, Navi BB, Rao VA, Faigeles BS, Conell C, et al., (2012b). Statin use during ischemic stroke hospitalization is strongly associated with improved poststroke survival. Stroke 43: 147-54.
12. García-Bonilla L, Campos M, Giralt D, Salat D, Chacõn P, Hernández-Guillamon M, et al., (2012). Evidence for the efficacy of statins in animal stroke models: a meta-analysis. J Neurochem 122: 233-43.
13. Gautier S, Ouk T, Petrault O, Caron J, Bordet R, (2009). Neutrophils contribute to intracerebral haemorrhages after treatment with recombinant tissue plasminogen activator following cerebral ischaemia. Br J Pharmacol 156: 673-679.
14. Giannopoulos S, Katsanos A, Tsivgoulis G, Marshall R, (2012). Statins and cerebral hemodynamics. J Cereb Blood Flow Metab 32: 1973-1976.
15. Greenwood J, Heasman SJ, Alvarez JI, Prat A, Lyck R, Engelhardt B, (2011). Review: leucocyte-endothelial cell crosstalk at the blood-brain barrier: a prerequisite for successful immune cell entry to the brain. Neuropathol Appl Neurobiol 37: 24-39.
16. Guo Q, Wang G, Namura S, (2010). Fenofibrate improves cerebral blood flow after middle cerebral artery occlusion in mice. J Cereb Blood Flow Metab 30: 70-8.
17. Jasińska-Stroschein M, Owczarek J, Wejman I, Orszulak-Michalak D, (2011). Novel mechanistic and clinical implications concerning the safety of statin discontinuation. Pharmacol Rep PR 63: 867-879.
18. Kawai H, Deguchi S, Deguchi K, Yamashita T, Ohta Y, Omote Y, et al., (2011). Protection against ischemic stroke damage by synergistic treatment with amlodipine plus atorvastatin in Zucker metabolic rat. Brain Res 1382: 308-314.
19. Kilic E, Reitmeir R, Kilic Ü, Caglayan AB, Beker MC, Kelestemur T, et al., (2014). HMG-CoA reductase inhibition promotes neurological recovery, peri-lesional tissue remodeling, and contralesional pyramidal tract plasticity after focal cerebral ischemia. Front Cell Neurosci 8: 422.
20. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). NC3Rs Reporting Guidelines Working Group. Br J Pharmacol 160: 1577-1579.
21. Kim H, Sawada N, Soydan G, Lee H, Zhou Z, Hwang S, et al., (2008). Additive effects of statin and dipyridamole on cerebral blood flow and stroke protection. J Cereb Blood Flow Metab 28: 1285-1293.
22. Liu X, Zhang Z, Zhang L, Morris D, Kapke A, Lu M, et al., (2006). Atorvastatin downregulates tissue plasminogen activator-aggravated genes mediating coagulation and vascular permeability in single cerebral endothelial cells captured by laser microdissection. J Cereb Blood Flow Metab 26: 787-796.
23. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
24. Ni Chroinin D, Asplund K, Asberg S, Callaly E, Cuadrado-Godia E, Diez-Tejedor E, et al., (2013). Statin therapy and outcome after ischemic stroke: systematic review and meta-analysis of observational studies and randomized trials. Stroke 44: 448-456.
25. Ouk T, Potey C, Laprais M, Gautier S, Hanf R, Darteil R, et al., (2014a). PPARα is involved in the multitargeted effects of a pretreatment with atorvastatin in experimental stroke. Fundam Clin Pharmacol 28: 294-302.
26. Ouk T, Gautier S, Pétrault M, Montaigne D, Maréchal X, Masse I, et al., (2014b). Effects of the PPAR-α agonist fenofibrate on acute and short-term consequences of brain ischemia. J Cereb Blood Flow Metab 34: 542-551.
27. Paumelle R, Staels B, (2008). Cross-talk between statins and PPARalpha in cardiovascular diseases: clinical evidence and basic mechanisms. Trends Cardiovasc Med 18: 73-8.
28. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al., (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands. Nucl Acids Res 42 (Database Issue): D1098-106.
29. Pétrault O, Ouk T, Gautier S, Laprais M, Gelé P, Bastide M, et al., (2005). Pharmacological neutropenia prevents endothelial dysfunction but not smooth muscle functions impairment induced by middle cerebral artery occlusion. Br J Pharmacol 144: 1051-8.
30. Prinz V, Laufs U, Gertz K, Kronenberg G, Balkaya M, Leithner C, et al., (2008). Intravenous rosuvastatin for acute stroke treatment: an animal study. Stroke 39: 433-8.
31. Rodríguez-Yáñez M, Dávalos A, Castillo J, (2008). Withdrawal from statins: implications for secondary stroke prevention and acute treatment. Int J Stroke 3: 85-87.
32. Saito T, Nito C, Ueda M, Inaba T, Kamiya F, Muraga K, et al., (2014). Continuous oral administration of atorvastatin ameliorates brain damage after transient focal ischemia in rats. Life Sci 94: 106-114.
33. Scheitz JF, Seiffge DJ, Tütüncü S, Gensicke H, Audebert HJ, Bonati LH, et al., (2014). Dose-related effects of statins on symptomatic intracerebral hemorrhage and outcome after thrombolysis for ischemic stroke. Stroke 45: 509-514.
34. Shehadah A, Chen J, Cui X, Roberts C, Lu M, Chopp M, (2010). Combination treatment of experimental stroke with Niaspan and simvastatin, reduces axonal damage and improves functional outcome. J Neurol Sci 294: 107-11.
35. Shimamura M, Sato N, Sata M, Kurinami H, Takeuchi D, Wakayama K, et al., (2007). Delayed postischemic treatment with fluvastatin improved cognitive impairment after stroke in rats. Stroke 38: 3251-8.
36. Suh J, Choi D, Chang H, Cho Y, Youn T, Chae I, et al., (2010). HMG-CoA reductase inhibitor improves endothelial dysfunction in spontaneous hypertensive rats via down-regulation of caveolin-1 and activation of endothelial nitric oxide synthase. J Kor Med Sci 25: 16-23.
37. Yanuck D, Mihos C, Santana O, (2012). Mechanisms and clinical evidence of the pleiotropic effects of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in central nervous system disorders: a comprehensive review. Int J Neurosci 122: 619-29.
38. Yenari M, Kauppinen T, Swanson R, (2010). Microglial activation in stroke: therapeutic targets. Neurother 7: 378-391.
39. Zhang L, Chopp M, Jia L, Cui Y, Lu M, Zhang ZG, (2009). Atorvastatin extends the therapeutic window for tPA to 6 h after the onset of embolic stroke in rats. J Cereb Blood Flow Metab 29: 1816-24.
40. del Zoppo GJ, (2009). Inflammation and the neurovascular unit in the setting of focal cerebral ischemia. Neuroscience 158: 972-982.